Draw/line
Home / Guides / 08

How strong is the evidence?

A simple way to grade the evidence behind peptide claims, from large human trials to animal-only data.

4 min read · By the Drawline team · Reviewed

Claims about peptides range from large clinical trials to a single rodent study. A simple grading habit helps.

AApproved, large human trials. Benefits and risks measured in thousands of people. Semaglutide and tirzepatide for their approved uses sit here.

BApproved for a narrow use. Solid human data for one condition, often used beyond it. Tesamorelin, approved for a specific HIV-related condition, is an example.

CSmall or early human studies. Suggestive, with short follow-up and few participants.

DAnimal and lab data only. Much of what is said about BPC-157 and TB-500 rests here. Neither is FDA-approved, and FDA has cited a lack of human safety data for peptides of this kind.

Questions to ask of any claim

  • Was it tested in humans, and how many?
  • Was there a control group?
  • Who paid for it, and who is repeating the claim?
  • Was the product tested the same thing you can actually obtain?

A lower grade does not prove a compound fails. It means nobody has shown that it works or that it is safe.

Source for FDA’s stated concerns: Polsinelli on peptide compounding.

This guide is for research and educational use. It is not medical advice. Confirm anything that affects your health with a licensed professional.